Pharvaris (PHVS) Valuation Check After Conference Data Support For Deucrictibant Combination Regimen

Pharvaris (NasdaqGS:PHVS) is back in focus after new conference data supported the safety of combining its deucrictibant extended release tablet for prophylaxis with immediate release capsules for treating hereditary angioedema breakthrough attacks.

See our latest analysis for Pharvaris.

The latest conference data seems to have kept interest in Pharvaris alive, with a 1-year total shareholder return of 67.82% and a 3-year total shareholder return above 2x. At the same time, the 90-day share price return of 5.30% points to steady rather than explosive momentum around the current US$28.63 level.

If this kind of clinical progress catches your attention, it can be worth widening the lens and scanning other potential healthcare names through our screener for 33 healthcare AI stocks

With shares around US$28.63, a very large modeled intrinsic discount and a value score of just 2 pull in different directions. Is Pharvaris still trading below what its progress suggests, or is the market already pricing in future growth?

DCF fair value versus a rich P/B ratio

At around $28.63, Pharvaris screens very cheaply against the SWS DCF model, which puts future cash flow value at $345.82, yet the stock carries a P/B ratio of 5.9x compared with 4.5x for peers and 2.6x for the wider US pharmaceuticals group.

The SWS DCF model estimates what a business might be worth by projecting its future cash flows and discounting them back to today. That process focuses on cash generation potential rather than current revenue or earnings, which is relevant for a late stage biopharma name with phase 3 programs and limited current revenue.

Pharvaris is currently loss making, reports less than $1m in revenue and is forecast to remain unprofitable over the next three years, so most of the modeled value sits in expected future cash flows if its pipeline succeeds. Against that, all liabilities come from higher risk external funding rather than customer deposits, and recent shareholder dilution means existing holders have already absorbed some of the funding cost of that growth path.

Investors weighing that very large modeled intrinsic discount also have to contend with a P/B of 5.9x that screens as expensive versus both direct peers and the broader industry, along with an analyst price target that is more than 20% above the current share price but comes with limited agreement between forecasters. Together, those signals point to a wide spread between what different models and market participants currently assume about Pharvaris's long term cash generation, and underline why understanding the SWS DCF model inputs can be useful before leaning too hard on any single fair value line in the sand.

Look into how the SWS DCF model arrives at its fair value.

Result: DCF Fair value of $345.82 (UNDERVALUED)

However, those DCF and price target gaps could close quickly if phase 3 data disappoints or if further equity funding adds to dilution pressures for existing holders.

Find out about the key risks to this Pharvaris narrative.

Another view on what the market is pricing in

While the SWS DCF model points to a very large gap between the current $28.63 share price and its $345.82 fair value estimate, Pharvaris trades on a P/B of 5.9x versus 4.5x for peers and 2.6x for the wider US pharmaceuticals group. That mix of deep DCF discount and rich balance sheet multiple raises a simple question: which signal should matter more for you right now?

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Pharvaris for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 54 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With that mix of excitement and caution, it helps to look at the full picture yourself and decide how the balance of risks and rewards stacks up for your portfolio. To see both sides clearly, start with the 1 key reward and 3 important warning signs.

Looking for more investment ideas?

If Pharvaris has sharpened your focus, do not stop here. Broaden your watchlist with other opportunities that could complement or balance a position like this.

• Spot potential mispricings by scanning companies that appear to offer more for less with the help of our 54 high quality undervalued stocks.
• Strengthen your income stream by reviewing companies that pair higher yields with staying power using the 12 dividend fortresses.
• Sleep a little easier by checking out companies that score better on resilience and risk using the 72 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com